Table 2.
Demographic and clinical characteristics of subjects at baseline after extraction by propensity score matching.
| Denosumab (n = 69) | Romosozumab (n = 69) | P value | |
|---|---|---|---|
| Age (years, mean ± SD) | 74.20 ± 11.32 | 75.83 ± 9.70 | 0.367 |
| BMI (kg/m2) | 21.15 ± 3.39 | 22.09 ± 3.24 | 0.192 |
| T-score | |||
| Lumbar spine | − 2.50 ± 1.13 | − 2.62 ± 1.25 | 0.322 |
| Total hip | − 2.55 ± 0.73 | − 2.57 ± 0.84 | 0.930 |
| Femoral neck | − 3.12 ± 0.62 | − 3.12 ± 0.82 | 0.870 |
| Prior vertebral fracture, n (%) | 26 (37.7) | 25 (36.2) | 1.000 |
| Prior non-vertebral fracture, n (%) | 12 (17.4) | 13 (18.8) | 1.000 |
| History of prior treatment, n (%) | |||
| Naïve | 42 (60.9) | 49 (70.1) | 0.281 |
| Switch | 27 (39.1) | 20 (29.0) | |
| Concomitant use of active vitamin D, n (%) | 12 (17.4) | 35 (50.7) | 0.612 |
| PINP (µg/L, IQR) | 56.8 [35.9, 84.3] | 68.6 [41.3, 99.8] | 0.086 |
| TRACP-5b (mU/dL, IQR) | 454.0 [350.5, 621.5] | 545.0 [353.0, 690.0] | 0.296 |
| Serum albumin (g/dL) | 4.12 ± 0.29 | 4.17 ± 0.34 | 0.104 |
| Serum-corrected Ca (mg/dL) | 9.35 ± 0.47 | 9.34 ± 0.37 | 0.761 |
| eGFR (mL/min/1.73 m2) | 70.36 ± 21.43 | 68.78 ± 21.9 | 0.472 |
| 25OHD (ng/mL) | 15.00 ± 6.32 | 16.35 ± 6.17 | 0.241 |
Data are expressed as the mean ± standard deviation (SD) or the number (%) of subjects. P1NP and TRACP-5b are expressed as median values.
BMI body mass index, P1NP procollagen type 1 N-terminal propeptide, TRACP-5b tartrate-resistant acid phosphatase isoform 5b, eGFR estimated glomerular filtration rate, 25OHD 25-hydroxyvitamin D; Differences between the groups were determined by ANOVA or Fisher’s exact test.